Therapy Areas: Cardiovascular
IONETIX announces FDA approval to begin production of N-13 Ammonia at Adler Imaging
12 November 2021 -

Isotope manufacturing company IONETIX reported on Thursday the receipt of the US FDA's approval for N-13 Ammonia manufacturing at Adler Institute for Advanced Imaging in Jenkintown PA.

Adler Imaging, which has been the leading independent PET/CT facility serving the greater Philadelphia area for nearly twenty years, will be using the N-13 Ammonia manufactured by IONETIX to perform Cardiac PET imaging, which is used to diagnose and risk stratify patients with coronary artery disease (CAD).

The company added that N-13 Ammonia has received the gold standard for its superior image quality and its ability to perform quantitative analysis of non-invasive cardiac imaging for the detection and evaluation of CAD.

Adler Imaging is IONETIX's fifth site approved by the US FDA and several more sites are underway. It will now bring its unique solution for N-13 Ammonia as a service to hospitals and outpatient office settings across the US, commented CEO Kevin Cameron.